Strong Financial Position and Promising Clinical Developments Position Spyre Therapeutics for Success
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $65
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Spyre Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results.
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
Spyre Therapeutics: Promising Future With Innovative IBD Treatments and Strategic Advancements
Spyre Therapeutics Q1 EPS $(0.62) Beats $(0.84) Estimate
Express News | Spyre Therapeutics Inc: Expected Cash Runway Into Second Half of 2028
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Press Release: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics | 10-Q: Q1 2025 Earnings Report
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)
Express News | Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (Ddw) 2025 Including up to Eight Months of Follow-up From an Ongoing Phase 1 Trial of Spy001
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight Months of Follow-up From an Ongoing Phase 1 Trial of SPY001
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO), Spyre Therapeutics (SYRE) and Herbalife (HLF)
Spyre Therapeutics Analyst Ratings
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, Its Novel Half-life Extended IL-23 Antibody
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27